Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.

Yukio Kadooka, Masao Sato, Akihiro Ogawa, Masaya Miyoshi, Hiroshi Uenishi, Hitomi Ogawa, Ken Ikuyama, Masatoyo Kagoshima, Takashi Tsuchida

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 10(8) colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (10(6) or 10(7) cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2 - 187·8 cm(2)). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 10(7), 10(6) or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8·5 % (95 % CI -11·9, -5·1; P< 0·01) in the 10(7) dose group, and by -8·2 % (95 % CI -10·8, -5·7; P< 0·01) in the 10(6) dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 10(8) cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.

Original languageEnglish
Pages (from-to)1696-1703
Number of pages8
JournalThe British journal of nutrition
Volume110
Issue number9
DOIs
Publication statusPublished - Nov 14 2013

Fingerprint

Adiposity
Milk
Randomized Controlled Trials
Stem Cells
Intra-Abdominal Fat
Probiotics
Waist Circumference
Lactobacillus gasseri
Adipose Tissue
Hip
Tomography
Control Groups

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. / Kadooka, Yukio; Sato, Masao; Ogawa, Akihiro; Miyoshi, Masaya; Uenishi, Hiroshi; Ogawa, Hitomi; Ikuyama, Ken; Kagoshima, Masatoyo; Tsuchida, Takashi.

In: The British journal of nutrition, Vol. 110, No. 9, 14.11.2013, p. 1696-1703.

Research output: Contribution to journalArticle

Kadooka, Y, Sato, M, Ogawa, A, Miyoshi, M, Uenishi, H, Ogawa, H, Ikuyama, K, Kagoshima, M & Tsuchida, T 2013, 'Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.', The British journal of nutrition, vol. 110, no. 9, pp. 1696-1703. https://doi.org/10.1017/S0007114513001037
Kadooka, Yukio ; Sato, Masao ; Ogawa, Akihiro ; Miyoshi, Masaya ; Uenishi, Hiroshi ; Ogawa, Hitomi ; Ikuyama, Ken ; Kagoshima, Masatoyo ; Tsuchida, Takashi. / Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. In: The British journal of nutrition. 2013 ; Vol. 110, No. 9. pp. 1696-1703.
@article{da1eb3c081ec4c00b282251547b91f30,
title = "Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.",
abstract = "Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 10(8) colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (10(6) or 10(7) cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2 - 187·8 cm(2)). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 10(7), 10(6) or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8·5 {\%} (95 {\%} CI -11·9, -5·1; P< 0·01) in the 10(7) dose group, and by -8·2 {\%} (95 {\%} CI -10·8, -5·7; P< 0·01) in the 10(6) dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 10(8) cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.",
author = "Yukio Kadooka and Masao Sato and Akihiro Ogawa and Masaya Miyoshi and Hiroshi Uenishi and Hitomi Ogawa and Ken Ikuyama and Masatoyo Kagoshima and Takashi Tsuchida",
year = "2013",
month = "11",
day = "14",
doi = "10.1017/S0007114513001037",
language = "English",
volume = "110",
pages = "1696--1703",
journal = "British Journal of Nutrition",
issn = "0007-1145",
publisher = "Cambridge University Press",
number = "9",

}

TY - JOUR

T1 - Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.

AU - Kadooka, Yukio

AU - Sato, Masao

AU - Ogawa, Akihiro

AU - Miyoshi, Masaya

AU - Uenishi, Hiroshi

AU - Ogawa, Hitomi

AU - Ikuyama, Ken

AU - Kagoshima, Masatoyo

AU - Tsuchida, Takashi

PY - 2013/11/14

Y1 - 2013/11/14

N2 - Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 10(8) colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (10(6) or 10(7) cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2 - 187·8 cm(2)). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 10(7), 10(6) or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8·5 % (95 % CI -11·9, -5·1; P< 0·01) in the 10(7) dose group, and by -8·2 % (95 % CI -10·8, -5·7; P< 0·01) in the 10(6) dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 10(8) cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.

AB - Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 10(8) colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (10(6) or 10(7) cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2 - 187·8 cm(2)). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 10(7), 10(6) or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8·5 % (95 % CI -11·9, -5·1; P< 0·01) in the 10(7) dose group, and by -8·2 % (95 % CI -10·8, -5·7; P< 0·01) in the 10(6) dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 10(8) cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.

UR - http://www.scopus.com/inward/record.url?scp=84891909634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891909634&partnerID=8YFLogxK

U2 - 10.1017/S0007114513001037

DO - 10.1017/S0007114513001037

M3 - Article

C2 - 23614897

AN - SCOPUS:84891909634

VL - 110

SP - 1696

EP - 1703

JO - British Journal of Nutrition

JF - British Journal of Nutrition

SN - 0007-1145

IS - 9

ER -